

# Observational study of patients with DMD theoretically treatable with exon skipping 53

## Hub Summary

PreU7-53 is an observational cohort study. This natural history study is designed to monitor upper limb muscle impairment in patients potentially treatable with AAV-mediated exon skipping.

**Study Number: NCT01385917**

## Description by Genethon

PreU7-53 is a natural history study. The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with Duchenne Muscular Dystrophy (DMD), potentially treatable with AAV-mediated exon 53 skipping.

## Primary Outcome Measures

PreU7-53 is a natural history study [Time Frame: Every year]

The objective is to monitor the clinical and radiological course of upper limb muscle impairment in patients with DMD, potentially treatable with AAV-mediated exon 53 skipping.

## Can I take part?

### Inclusion Criteria

- ✓ Diagnosis of Duchenne muscular dystrophy confirmed by at least genetic testing, theoretically treatable by exon 53 skipping.
- ✓ Age between 12 and <20 years old.
- ✓ Non ambulant patients (ie; inability to walk more than 10 meters without any of assistance).
- ✓ Patients covered by a national health insurance scheme.
- ✓ Signed informed consent.

### Exclusion Criteria

- ✗ Patient incapable of sitting upright in a wheelchair for at least one hour.
- ✗ Patients with severe intellectual impairment preventing them from fully understanding the exercises to be performed.
- ✗ Recent (less than 6 months ago) upper limb surgery or trauma. This criteria is however not definitive. Patients who have undergone upper limb surgery or trauma may nonetheless be enrolled once the 6 month period is over.
- ✗ Known immune deficiency.
- ✗ Contraindications to NMR exams

For contact details and to find out more, please refer to [dmdhub.org](http://dmdhub.org).



**Duchenne  
UK**


PDF created on 29/08/2025.

## Trial Status

### Trial complete

 **UK Locations**  
London - GOSH, Trial complete/terminated

 **Trial Sponsor**  
Genethon

 **Phase**  
Observational


 **Length Of Participation**  
TBC


 **Recruitment Target**  
45

 **Ambulatory**  
Non-ambulant

 **Therapeutic Category**  
Natural History

 **Age**  
12-20

 **Mutation Specific**  
Mutation specific therapies, Amenable to treatments with Exon 53 skipping

 **Muscle Biopsy**  
No Muscle Biopsy Required

[dmdhub.org](http://dmdhub.org)

  
**DMD HUB**